secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001628280-25-037840
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine shareholders approve repricing of up to 8.3M stock options to $4.04/sh
--------------------------------------------------------------------------------

- Stockholders approved one-time repricing of eligible options held by employees, execs, and board; exercise price reduced to $4.04 (Aug 1 closing price).
- Covers up to 8,285,387 shares; options revert to original price if exercised before 1-yr (employees) or 18-mo (executives/board) retention period unless certain conditions.
- Final vote: 71.6M for, 13.5M against, 0.1M abstain.
- CEO Allan Reine and other named exec officers are eligible optionholders.
- Repricing intended as retention mechanism; original terms except exercise price remain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828025037840/0001628280-25-037840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828025037840/prme-20250801.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-037840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer